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Background/aims: The frequency of Human Leucocyte Antigens/alleles associated with rapid
progression from Human Immunodeﬁciency Virus infection to Acquired Immunodeﬁciency
Syndrome was evaluated in Brazilian patients with Acquired Immunodeﬁciency Syndrome
with  and without Toxoplasmic Encephalitis.
Methods: 114 patients with Acquired Immunodeﬁciency Syndrome (41 with Toxoplasmic
Encephalitis, 43 with anti-Toxoplasma gondii antibodies, without Toxoplasmic Eencephali-
tis, and 30 without anti-Toxoplasma gondii antibodies circulating and without Toxoplasmic
Encephalitis) were studied.
Results: Human Leucocyte Antigens/alleles associated with rapid progression to Acquired
Immunodeﬁciency Syndrome, particularly HLA-B35, -DR3, and -DR1 allele group, were
signiﬁcantly less represented in patients with Toxoplasmic Encephalitis and Acquired
Immunodeﬁciency Syndrome.
Conclusion: The presence of these Human Leucocyte Antigens/Alleles that predispose toAcquired Immunodeﬁciency Syndrome progression was associated with resistance to Tox-
oplasmic Encephalitis among Human Immunodeﬁciency Virus-1 carriers.
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Statistical  analysis
HLA antigen and HLA allele group frequencies were calculated
by direct counting. The strength of the association between116  b r a z j i n f e c t d 
Introduction
Human leukocyte antigens (HLA) genes have been reported
to be associated with increased susceptibility to the devel-
opment of speciﬁc disease or with progression to AIDS
outcomes.1–3 The progression from human immunodeﬁciency
virus (HIV) infection to AIDS has been strongly associated
with HLA-A1-Cw7-B8-DR3-DQ2 and HLA-A11-Cw4-B35-DR1-
DQ1 haplotypes, conferring a high risk of rapid progression to
AIDS.4–7 It has been assumed that associations between pro-
gression to AIDS and particular HLA alleles reﬂect differential
antigen presentation by classes I or II molecules exhibiting
particular motifs in the peptide binding groove.8 For exam-
ple, the most harmful effects of HLA-B*35 are seen with the
molecules encoded by the HLA-B*35:02 and B*35:03 alleles,
which have proline at anchor position 2 of their loaded pep-
tide and a non-tyrosine residue at position 9.9 For instance,
the HLA-B*35:01 molecule containing tyrosine at position 9
does not have any substantial effect on disease prognosis.
While both HLA-B*35 subtypes can equally induce a cytotoxic
T lymphocyte (CTL) response, viral load was cleared less effec-
tively by non-tyrosine-containing HLA-B*35:02 and B*35:03
molecules compared with HLA-B*35:01.10 It may, therefore,
be possible that altered epitope recognition by HLA-B*35:02
and B*35:03 will induce CTL that may not speciﬁcally function
against HIV-1-infected cells.11
Toxoplasma gondii infection is widespread in humans, with
estimated infection rates ranging from 50% to 80% of the gen-
eral population in South America.12 In some areas of Southern
Brazil, the prevalence of antibodies against T. gondii may be as
high as 98%.13,14 Toxoplasmosis in the immunocompromised
host is most probably due to reactivation of a previous latent
infection and can be life-threatening.15 Encephalitis is the
most important manifestation of toxoplasmosis in immuno-
suppressed patients as it causes severe damage and death.16
It is estimated that in countries with a high prevalence of T.
gondii,  toxoplasmic encephalitis is the most common cerebral
lesion in HIV patients.17
Few studies reported an association between HLA mark-
ers and toxoplasmic encephalitis in AIDS patients.18–21 We
have previously reported that susceptibility to toxoplasmic
retinochoroiditis was associated with HLA alleles related with
rapid progression to AIDS,22 and the availability of genetic
markers for other AIDS severe complications may discrimi-
nate patients with poor prognosis. To further explore whether
HLA markers associated with rapid progression to AIDS could
also be associated with the development of toxoplasmic
encephalitis, we  evaluated these markers in Brazilian AIDS
patients with or without toxoplasmic encephalitis.
Material  and  methods
PatientsThe study was conducted on 114 adult HIV-infected patients
(81 males) aged 21–59 years (median = 33) presenting AIDS,
diagnosed 1–108 months (median = 22) before inclusion
in this study. Forty-one patients experienced toxoplasmic 1 6;2  0(2):115–118
encephalitis, diagnosed clinically and by brain computerized
tomography and by the presence of antibody against T. gondii
(Group 1). Two additional AIDS patient groups without toxo-
plasmic encephalitis were studied; i.e., a group of 43 patients
with positive anti-T gondii antibodies but without toxoplasmic
encephalitis (Group 2), and 30 patients with neither anti-
T. gondii antibodies nor toxoplasmic encephalitis (Group 3).
Patients were selected from the Acquired Immunodeﬁciency
Outpatient Clinic at the University Hospital of the Faculty of
Medicine of Ribeirão Preto, University of São Paulo, Brazil. A
total of 161 healthy bone marrow donors from the Univer-
sity Hospital of Faculty of Medicine of Ribeirão Preto with no
known infectious, chronic, or autoimmune disorders were also
studied.
Ethical  aspects
The local Ethics Committee of the University Hospital of Fac-
ulty of Medicine of Ribeirão Preto and the National Brazilian
Ethics Committee approved the study protocol, and informed
consent was obtained from all individuals (HCFMRP-USP #
8992/2001 and CONEP # 203/2002).
Anti-T.  gondii  antibodies
The search for anti-T. gondii antibodies in serum was per-
formed by indirect immunoﬂuorescence by the method of
Camargo23 using an anti-human IgG ﬂuorescent conjugate
(Bio-Meriéux). Serum samples with >1/16 titers were consid-
ered to be positive.
HLA  typing
HLA class I antigens expressed on the surface of peripheral
blood lymphomononuclear cells were typed using a microlym-
phocytotoxity assay.24 DNA was obtained from peripheral
blood mononuclear cells using a salting out procedure. HLA
class II allele typing was performed using commercial kits
(One Lambda, Canoga Park, CA), as previously described.25
HLA  speciﬁcities  associated  with  the  rate  of  progression  to
AIDS
Since HLA-A1, A11, B8, B35, DR3, DR1, DQ2, DQ1 antigens have
been described in the literature in association with rapid pro-
gression to AIDS4,26 in many  ethnic groups, these markers
were considered for analysis in the present study.toxoplasmic encephalitis and HLA speciﬁcities was evaluated
calculating the relative risk (RR) and Odds Ratio (OR). The
Fisher’s exact test was used for comparisons, and it was con-
sidered to be signiﬁcant at p < 0.05.
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Table 1 – Frequency of human leukocyte antigens (HLA) associated with rapid progression to AIDS in Brazilian AIDS
patients presenting with: (i) toxoplasmic encephalitis (Group 1); (ii) antibody against T. gondii but without toxoplasmic
encephalitis (Group 2); and (iii) negative serology for T. gondii and without toxoplasmic encephalitis (Group 3). The
frequencies of HLA among healthy controls are also shown.
HLA Group 1 (n = 41) Group 2 (n = 43) Group 3 (n = 30) Healthy controls
(n = 161)
Group Comparisons (p-values)
1 × 2 1 × 3 2 × 3
HLA-A11 4 (10%) 2 (5%) 2 (7%) 19 (12%) NS NS NS
HLA-B35 4 (10%) 6 (14%) 14 (47%) 76 (47%)
(p = 0.0003 × G1)
NS 0.0007 0.0031
HLA-DR1 5 (12%) 10 (23%) 3 (10%) 24 (15%) NS NS NS
HLA-DQ1 17 (42%) 36 (84%) 16 (53%) 140 (87%)
(p = 0.0001 × G1)
0.0001 NS 0.008
NS, non-signiﬁcant comparisons; × G1, comparisons to Group 1.
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LA  proﬁle  according  to  the  presence  of  toxoplasmic
ncephalitis
he frequency of HLA-B35 antigen was signiﬁcantly decreased
mong AIDS patients presenting toxoplasmic encephalitis
Group 1) in comparison to AIDS patients with neither anti-
. gondii antibodies nor toxoplasmic encephalitis (Group 3)
p = 0.0007), presenting a RR = 0.20 and an OD = 0.12 (Table 1).
imilar results were observed when the group of toxoplas-
ic  encephalitis AIDS patients (Group 1) were compared
ith healthy controls (p = 0.0003) and a RR = 0.20 and an
D = 0.12 (Table 1). When the HLA-B35 antigen frequency
as compared between AIDS patients without toxoplasmic
ncephalitis (Group 2 and Group 3) its frequency was sig-
iﬁcantly decreased among AIDS patients presenting with
nti-T. gondii antibodies (Group 2) (p = 0.0031), with a RR = 0.29
nd an OD = 0.18 (Table 1). However, the comparison of the
requency of HLA-B35 between patients with positive anti-T.
ondii antibodies, with and without toxoplasmic encephali-
is (Group 1 and Group 2), showed no signiﬁcant difference
Table 1).
On the other hand, the frequency of HLA-DQB1*01 allele
roup was signiﬁcantly decreased among AIDS patient pre-
enting toxoplasmic encephalitis (Group 1) in comparison
o AIDS patient presenting anti-T. gondii antibodies but
ithout toxoplasmic encephalitis (Group 2) p = 0.0001), and
ith a RR = 0.49 and an OD = 0.13 (Table 1). Similar results
ere observed when the AIDS group with toxoplasmic
ncephalitis (Group 1) were compared with healthy con-
rols (p = 0.0001), with a RR = 0.47 and an OD = 0.10 (Table 1).
hen the HLA-DQB1*01 allele group frequency was compared
etween AIDS patients without toxoplasmic encephalitis
Group 2 and Group 3) its frequency was signiﬁcantly
ecreased among those without anti-T. gondii antibodies
Group 3) (p = 0.008), conferring a RR = 1.57 and an OD = 4.50
Table 1).The frequencies of other HLA markers associated with
apid progression to AIDS were closely similar among AIDS
atients and healthy controls.Discussion
Several reports examining the role of HLA antigens/alleles in
AIDS susceptibility have been published5 and the haplotypes
encompassing HLA-B35 antigens were consistently associated
with rapid progression to AIDS in several populations.27 HLA-
B*35 alleles have been classiﬁed into two groups based on the
residue at pocket 9 (P9) of the peptide binding groove. The PY
group binds mainly to a tyrosine (Y) at P9, whereas the Px
group has a preference for smaller hydrophobic residues such
as leucine, methionine, or valine, and does not bind to tyrosine
at P9.9 HLA-B*35:02 and B*35:03 alleles, which code part of the
Px group, have been associated with an especially poor HIV
disease outcome.10 The possible mechanisms for this asso-
ciation remain unknown, but it has been suggested that the
greater ability of the HLA-B*35:01 (PY) molecule to present HIV
peptides (Gag) compared to HLA-B*35:02/35:03 molecules is a
key difference affecting HIV disease outcome.28 Furthermore,
HLA-B35:16 another member of the PY group, was the worst
HIV-peptide binding molecule among all B35 subtypes and was
associated with the highest viral load. Therefore, the detri-
mental effect of HLA-B35 is unlikely to be related exclusively
to PY/Px groups. Other factors, such as the ﬁne speciﬁcity of
the HIV peptides presented by different B35 molecules, may
play a role, affecting the nature of the CTL response.29
Few studies have focused on the evaluation of HLA anti-
gens/alleles in toxoplasmic infection among AIDS patients.
Concerning cerebral toxoplasmosis, the study conducted in
Caucasian North American patients with AIDS have reported
an association of the HLA-DQ3 antigen with susceptibil-
ity, and HLA-DQ1 antigen with resistance to toxoplasmic
encephalitis.19,20 In the present study, we  found a similar
association; i.e., HLA-DQ1 conferring resistance to toxoplas-
mic  encephalitis in Brazilian AIDS patients. Additionally, Mack
et al. studying transgenic mice for DQ human genes, demon-
strated that the human DQB1 gene, and to a lesser extent DQ3
gene, confers protection against T. gondii,  corroborating the
idea that certain DQB1 genes are associated with protection
against this pathogenic protozoan.
This is the ﬁrst study evaluating the frequency of HLA
markers in Brazilian AIDS patients, a mixed population,
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presenting with cerebral toxoplasmic disease. The ﬁndings
suggest that the frequency of HLA markers associated with
rapid progression to AIDS, in particular the HLA-DQB1*01 allele
group and HLA-B35 antigen, were less represented among tox-
oplasmic encephalitis AIDS patients. The frequency of T. gondii
infection in Brazilian AIDS patients can be as high as 98%.13
Therefore, the presence of these HLA markers may confer
resistance to the development of toxoplasmic encephalitis,
which are different from those markers associated with rapid
progression to AIDS.
In conclusion, AIDS patients presenting HLA-DQBl*01 allele
group appear to be resistant to the development of toxoplas-
mic  encephalitis, since the frequency of this allele was lower
in AIDS patients presenting encephalitis in relation to AIDS
patients presenting only the infection (anti-T. gondii antibod-
ies). The present study suggests that HLA-DQB1 typing, better
than the HLA-B, may help on decisions regarding toxoplasmo-
sis prophylaxis. Further studies will be required to determine
if genetic control of susceptibility to toxoplasmic encephalitis
is similar in AIDS patients of other ethnicities.
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